ReviewDrug delivery2020
Albumin-based cancer therapeutics for intraperitoneal drug delivery: a review.
Review in Drug delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 80 citations in OpenAlex.
- Population pharmacokinetics and pharmacodynamics of intraperitoneal aerosolized nanoparticle albumin-bound paclitaxel (nab-PTX) and metabolites.British journal of clinical pharmacology · 2026Article
- Nano Biomaterials in Drug Delivery and Tissue Engineering.Current drug delivery · 2026Review
- Human Albumin-enriched Peritoneal Dialysis: A Novel Approach to Manage Refractory Ascites and Kidney Dysfunction in Decompensated Advanced Chronic Liver Disease.Journal of clinical and translational hepatology · 2025Article
- Albumin conjugated with WQPDTAHHWATL and GRFLTGGTGRLLRIS peptide improves targeted docetaxel delivery for prostate cancer: anResearch in pharmaceutical sciences · 2025Article
- Organic-solvent mediated self-assembly of protoporphyrin IX with human serum albumin.International journal of biological macromolecules · 2025Article
- Synthesis of Bovine Serum Albumin-Coated Magnetic Single-Walled Carbon Nanotubes as a Delivery System for Mitoxantrone.ACS omega · 2025Article
- Clinical Prognostic Value of C-Reactive Protein-Albumin-Lymphocyte Index (CALLY) in Patients with Stage III Breast Cancer.Breast cancer (Dove Medical Press) · 2025Article
- Design and Characterization of Novel Polymeric Hydrogels with Protein Carriers for Biomedical Use.International journal of molecular sciences · 2024Article
- The Role of Medium Polarity in the Efficiency of Albumin Binding with Hydrophobic Ligands: Experimental Studies and a Molecular Dynamics Investigation.International journal of molecular sciences · 2024Article
- Combined Nabpaclitaxel pressurized intraPeritoneal aerosol chemotherapy with systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic cancer peritoneal metastases: protocol of single-arm, open-label, phase II trial (Nab-PIPAC trial).Pleura and peritoneum · 2024Article
- Rationalized landscape on protein-based cancer nanomedicine: Recent progress and challenges.International journal of pharmaceutics: X · 2024Review
- Half-life extension of single-domain antibody-drug conjugates by albumin binding moiety enhances antitumor efficacy.MedComm · 2024Article
- Factors Affecting the Synthesis of Bovine Serum Albumin Nanoparticles Using the Desolvation Method.Nanotechnology, science and applications · 2024Review
- Unveiling the Metabolic Maze: FDG PET/CT Findings in Peritoneal Carcinomatosis - A Case Series.Asia Oceania journal of nuclear medicine & biology · 2024Article
- Albumin Nanoparticle-Based Drug Delivery Systems.International journal of nanomedicine · 2024Review
- An Analysis of Preoperative Inflammatory Indicators That Influence the Drainage Tube Retention Time in Patients with Breast Cancer Surgery.Breast cancer (Dove Medical Press) · 2024Article
- Preclinical Activity of Two Paclitaxel Nanoparticle Formulations After Intraperitoneal Administration in Ovarian Cancer Murine Xenografts.International journal of nanomedicine · 2024Article
- Protein-Targeting Drug Discovery.Biomolecules · 2023Article
- Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Effectiveness of Albumin-Fused Thioredoxin against 6-Hydroxydopamine-Induced Neurotoxicity In Vitro.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Albumin is a remarkable carrier protein with multiple cellular receptor and ligand binding sites, which are able to bind and transport numerous endogenous and exogenous compounds. The development of albumin-bound drugs is gaining increased importance in the targeted delivery of cancer therapy. Intraperitoneal (IP) drug delivery represents an attractive strategy for the local treatment of peritoneal metastasis (PM). PM is characterized by the presence of widespread metastatic tumor nodules on the peritoneum, mostly originating from gastro-intestinal or gynaecological cancers. Albumin as a carrier for chemotherapy holds considerable promise for IP delivery in patients with PM. Data from recent (pre)clinical trials suggest that IP albumin-bound chemotherapy may result in superior efficacy in the treatment of PM compared to standard chemotherapy formulations. Here, we review the evidence on albumin-bound chemotherapy with a focus on IP administration and its efficacy in PM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.